Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10516
- Development stage
- Phase 2
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10516 is an orally bioavailable small molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), developed for its potential antineoplastic (anti-cancer) activity. By inhibiting HIF-2α, a transcription factor involved in cellular response to hypoxia and tumor progression, HS-10516 aims to suppress tumor growth and survival under low oxygen conditions. The drug is being developed by Jiangsu Hansoh Pharmaceutical and its affiliate Shanghai Hansoh Biomedical, with clinical trials focused on advanced solid tumors, renal cell carcinoma, and von Hippel-Lindau (VHL) syndrome-associated tumors. As of 2025, it is in Phase 1 clinical development in China.
- Other names
- HIF-2alpha inhibitor HS-10516HIF2alpha inhibitor HS-10516HIF 2alpha inhibitor HS-10516NKT2152NKT-2152NKT 2152
02
Targets
EPAS1 (Hypoxia-inducible factor 2-alpha)
Beyond the preview
Go deeper on HS-10516.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10516.